ReadON
Commercial- Indications
- Cognitive assessment, Cognitive therapy
Company intelligence / Profile preview
Orange Neurosciences has developed AI-powered digital platforms—ReadON and Titli—for the assessment and remediation of cognitive disorders such as dyslexia, ADHD, autism spectrum disorder, dementia/MCI, aphasia, and more. Their solutions are delivered via SaaS to healthcare providers in both English and French. The company’s products are not intended as medical diagnosis or treatment but serve as aids to support clinical decision-making or research. Clinical results are not published in peer-reviewed journals but the platforms have been adopted by schools/colleges/workplaces with reported improvements in reading fluency/executive function.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Orange Neurosciences.